Weight Loss Results from Clinical Trials
Wegovy (semaglutide 2.4 mg weekly) shows greater average weight loss than Ozempic (semaglutide up to 1 mg weekly, primarily for diabetes). In the STEP 1 trial, Wegovy users lost 15% of body weight (about 35 pounds for a 230-pound person) after 68 weeks, versus 2.4% on placebo.[1] Ozempic's SUSTAIN trials for diabetes reported 8-12% weight loss at 1 mg doses over 56-104 weeks, with less emphasis on obesity patients.[2][3]
Real-world data aligns: A 2023 study of over 18,000 patients found Wegovy users averaging 15.8% loss at 1 year, compared to 12.3% for Ozempic.[4]
Why Wegovy Outperforms on Weight Loss
Higher dose drives the difference—Wegovy uses 2.4 mg weekly, double Ozempic's max approved dose. Both mimic GLP-1 hormone to reduce appetite and slow gastric emptying, but escalation to 2.4 mg sustains stronger effects longer. Head-to-head isn't direct (no identical trials), but dose-response data from STEP trials confirms more semaglutide yields more loss.[1][5]
Dosing Schedules and Usage
Both are weekly subcutaneous injections with similar titration: start at 0.25 mg, ramp up over 4-16 weeks to minimize nausea. Wegovy caps at 2.4 mg; Ozempic at 2 mg (newer approval) but typically 1 mg for weight. Ozempic is FDA-approved for type 2 diabetes (off-label for weight); Wegovy solely for chronic weight management (BMI ≥30 or ≥27 with comorbidities).[6][7]
| Aspect | Wegovy | Ozempic |
|--------|--------|---------|
| Max Dose | 2.4 mg/week | 1-2 mg/week |
| Primary Indication | Obesity/weight loss | Type 2 diabetes |
| Avg. Weight Loss (1 year) | 15% | 8-12% |
| Cost (list price, 4 weeks) | ~$1,350 | ~$1,000 |
Side Effects and Safety Comparison
Gastrointestinal issues dominate both: nausea (44% Wegovy vs. 20-44% Ozempic), vomiting, diarrhea. Wegovy reports slightly higher rates due to dose but similar dropout (4-7%). Both carry black-box warnings for thyroid tumors (rodent data); rare pancreatitis or gallbladder risks. No major differences in cardiovascular safety—both reduce events in diabetes trials.[1][2][8]
Patients on Wegovy often note more intense early side effects but better tolerance long-term.
Cost, Access, and Insurance Coverage
Ozempic is cheaper out-of-pocket (~$900-1,000/month) and more widely covered for diabetes, but weight-loss use faces restrictions. Wegovy (~$1,300-1,400/month) has growing obesity coverage via Medicare/Medicaid expansions. Shortages hit both in 2023-2024, favoring Ozempic availability.[9][10]
Compounding versions exist amid shortages, but FDA warns of risks.
Alternatives if Neither Fits
For stronger loss, consider tirzepatide (Mounjaro/Zepbound): 21% average in SURMOUNT trials, outperforming semaglutide head-to-head (15% vs. 8% at 72 weeks).[11] Oral semaglutide (Rybelsus) yields less (5-6%). Surgery or older drugs like phentermine lag behind GLP-1s.
Sources
[1]: NEJM - STEP 1 Trial
[2]: NEJM - SUSTAIN 6
[3]: Novo Nordisk - Ozempic Prescribing Info
[4]: JAMA - Real-World Weight Loss (2023)
[5]: Wilding et al., Lancet (2021)
[6]: FDA - Wegovy Label
[7]: FDA - Ozempic Label
[8]: Novo Nordisk Safety Data
[9]: GoodRx Pricing
[10]: FDA Shortage List
[11]: NEJM - SURMOUNT-1